AU2015346343B2 - Macrocyclic peptides useful as immunomodulators - Google Patents

Macrocyclic peptides useful as immunomodulators Download PDF

Info

Publication number
AU2015346343B2
AU2015346343B2 AU2015346343A AU2015346343A AU2015346343B2 AU 2015346343 B2 AU2015346343 B2 AU 2015346343B2 AU 2015346343 A AU2015346343 A AU 2015346343A AU 2015346343 A AU2015346343 A AU 2015346343A AU 2015346343 B2 AU2015346343 B2 AU 2015346343B2
Authority
AU
Australia
Prior art keywords
compound
acceptable salt
resin
dmf
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015346343A
Other languages
English (en)
Other versions
AU2015346343A1 (en
Inventor
Kenneth M. Boy
Eric P. Gillis
Kevin W. Gillman
Jason Goodrich
David R. Langley
Claudio Mapelli
Nicholas A. Meanwell
Eric Mull
Michael A. Poss
Paul Michael Scola
Li-Qiang Sun
Yunhui Zhang
Qian Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54704111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015346343(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2015346343A1 publication Critical patent/AU2015346343A1/en
Application granted granted Critical
Publication of AU2015346343B2 publication Critical patent/AU2015346343B2/en
Priority to AU2020217406A priority Critical patent/AU2020217406A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015346343A 2014-11-14 2015-11-12 Macrocyclic peptides useful as immunomodulators Active AU2015346343B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020217406A AU2020217406A1 (en) 2014-11-14 2020-08-13 Macrocyclic peptides useful as immunomodulators

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462079944P 2014-11-14 2014-11-14
US62/079,944 2014-11-14
US201562111388P 2015-02-03 2015-02-03
US62/111,388 2015-02-03
US201562204689P 2015-08-13 2015-08-13
US62/204,689 2015-08-13
PCT/US2015/060265 WO2016077518A1 (en) 2014-11-14 2015-11-12 Macrocyclic peptides useful as immunomodulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020217406A Division AU2020217406A1 (en) 2014-11-14 2020-08-13 Macrocyclic peptides useful as immunomodulators

Publications (2)

Publication Number Publication Date
AU2015346343A1 AU2015346343A1 (en) 2017-06-29
AU2015346343B2 true AU2015346343B2 (en) 2020-05-14

Family

ID=54704111

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015346343A Active AU2015346343B2 (en) 2014-11-14 2015-11-12 Macrocyclic peptides useful as immunomodulators
AU2020217406A Abandoned AU2020217406A1 (en) 2014-11-14 2020-08-13 Macrocyclic peptides useful as immunomodulators

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020217406A Abandoned AU2020217406A1 (en) 2014-11-14 2020-08-13 Macrocyclic peptides useful as immunomodulators

Country Status (33)

Country Link
US (4) US9856292B2 (enExample)
EP (2) EP3218392B1 (enExample)
JP (1) JP6804442B2 (enExample)
KR (1) KR102569176B1 (enExample)
CN (2) CN114652813A (enExample)
AU (2) AU2015346343B2 (enExample)
CA (1) CA2967344C (enExample)
CL (1) CL2017001171A1 (enExample)
CO (1) CO2017004736A2 (enExample)
CY (1) CY1123598T1 (enExample)
DK (1) DK3218392T3 (enExample)
EA (1) EA036279B1 (enExample)
ES (1) ES2819285T3 (enExample)
HR (1) HRP20201692T1 (enExample)
HU (1) HUE051659T2 (enExample)
IL (1) IL252235B (enExample)
LT (1) LT3218392T (enExample)
MA (1) MA39285A (enExample)
MX (1) MX384024B (enExample)
MY (1) MY184870A (enExample)
PE (1) PE20171332A1 (enExample)
PH (1) PH12017500858A1 (enExample)
PL (1) PL3218392T3 (enExample)
PT (1) PT3218392T (enExample)
RS (1) RS60940B1 (enExample)
SG (1) SG11201703754SA (enExample)
SI (1) SI3218392T1 (enExample)
SM (1) SMT202000578T1 (enExample)
TN (1) TN2017000183A1 (enExample)
TW (1) TWI700301B (enExample)
UY (1) UY36400A (enExample)
WO (1) WO2016077518A1 (enExample)
ZA (1) ZA201703295B (enExample)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2928474T3 (en) 2012-12-07 2019-02-11 Chemocentryx Inc Diazollactamer
US10538555B2 (en) 2014-09-11 2020-01-21 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US10406251B2 (en) 2014-11-25 2019-09-10 Bristol-Myers Squibb Company PD-L1 binding polypeptides for imaging
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
KR102622891B1 (ko) 2015-05-21 2024-01-08 케모센트릭스, 인크. Ccr2 조절제
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) * 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
RU2745195C2 (ru) 2016-04-07 2021-03-22 Кемосентрикс, Инк. Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
LT3458111T (lt) * 2016-05-19 2021-05-25 Bristol-Myers Squibb Company Pet vizualizacijos imunomoduliatoriai
JP7016323B2 (ja) 2016-06-01 2022-02-21 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ－ｌ１結合ポリペプチドを用いるｐｅｔ造影
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
MA46535A (fr) 2016-10-14 2019-08-21 Prec Biosciences Inc Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b
EP3535280B1 (en) * 2016-11-07 2022-03-16 Bristol-Myers Squibb Company Immunomodulators
EP3548515A1 (en) 2016-12-01 2019-10-09 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
US11066445B2 (en) * 2017-06-23 2021-07-20 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of PD-1
KR102677442B1 (ko) 2017-09-25 2024-06-20 케모센트릭스, 인크. 케모카인 수용체 2(ccr2) 길항제 및 pd-1/pd-l1 억제제를 사용하는 병용 요법
CN111051332B (zh) 2017-10-03 2024-09-06 百时美施贵宝公司 免疫调节剂
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CA3082328A1 (en) 2017-11-14 2019-05-23 Green Cross Lab Cell Corporation Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
ES2991280T3 (es) 2018-01-08 2024-12-03 Chemocentryx Inc Antagonistas de CCR2 para el tratamiento del linfoma cutáneo de linfocitos T
TWI740099B (zh) * 2018-02-01 2021-09-21 大陸商江蘇恒瑞醫藥股份有限公司 含人胰島素類似物的醯化衍生物的藥物組合物及其製備方法
WO2019152801A1 (en) * 2018-02-02 2019-08-08 University Of Washington Caged amino acids for controlled metabolic incorporation and methods of use
CN108409830B (zh) * 2018-02-05 2021-04-23 郑州大学 一种人pd-1蛋白胞外段亲和环肽c8及其应用
SI3752501T1 (sl) 2018-02-13 2023-08-31 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
EP3810109B1 (en) 2018-05-31 2024-08-07 Peloton Therapeutics, Inc. Compounds and compositions for inhibiting cd73
MX2020012939A (es) 2018-05-31 2021-02-15 Ono Pharmaceutical Co Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios.
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
TWI855000B (zh) 2018-10-11 2024-09-11 日商小野藥品工業股份有限公司 Ｓｔｉｎｇ促效化合物
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
CA3117556A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
TWI721624B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
JP7350871B2 (ja) 2019-03-07 2023-09-26 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ２’３’－環状ジヌクレオチドおよびそのプロドラッグ
WO2020198676A1 (en) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
WO2020198672A1 (en) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
CN113853383A (zh) * 2019-05-21 2021-12-28 百时美施贵宝公司 免疫调节剂
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CN114127315A (zh) 2019-05-30 2022-03-01 百时美施贵宝公司 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
KR20220016156A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐
BR112022002098A2 (pt) 2019-08-05 2022-04-12 Nat Cancer Ct Biomarcadores para determinar a eficácia de inibidores da via de sinalização imune
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US20220348653A1 (en) 2019-09-22 2022-11-03 Bristol-Myers Squibb Company Quantitative Spatial Profiling for LAG-3 Antagonist Therapy
MY208114A (en) 2019-09-30 2025-04-16 Gilead Sciences Inc Hbv vaccines and methods treating hbv
BR112022008191A2 (pt) 2019-11-08 2022-07-12 Bristol Myers Squibb Co Terapia com antagonista de lag-3 para melanoma
CN116057068A (zh) 2019-12-06 2023-05-02 精密生物科学公司 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶
JP2023510737A (ja) * 2020-01-06 2023-03-15 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤
KR20220155332A (ko) * 2020-03-16 2022-11-22 브리스톨-마이어스 스큅 컴퍼니 면역조정제
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2021202501A1 (en) 2020-03-30 2021-10-07 Bristol-Myers Squibb Company Immunomodulators
JPWO2021206158A1 (enExample) 2020-04-10 2021-10-14
US20230151024A1 (en) 2020-04-10 2023-05-18 Ono Pharmaceutical Co., Ltd. Sting agonistic compound
JP2023524813A (ja) * 2020-05-08 2023-06-13 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤
CN113754736A (zh) * 2020-06-02 2021-12-07 南京礼威生物医药有限公司 含酰肼结构的pd-l1环肽抑制剂
AU2021331476A1 (en) 2020-08-28 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
KR20230061430A (ko) 2020-08-31 2023-05-08 브리스톨-마이어스 스큅 컴퍼니 세포 국재화 시그너쳐 및 면역요법
WO2022066635A1 (en) 2020-09-22 2022-03-31 Avidea Technologies, Inc. Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
IL301907A (en) 2020-10-23 2023-06-01 Bristol Myers Squibb Co Lag-3 antagonist therapy for lung cancer
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
KR20230160321A (ko) * 2021-03-24 2023-11-23 브리스톨-마이어스 스큅 컴퍼니 면역조정제
EP4313127A1 (en) 2021-03-29 2024-02-07 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
TW202348237A (zh) 2021-05-13 2023-12-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
WO2022261301A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359389A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN113461519A (zh) * 2021-08-12 2021-10-01 浙江泽瑞生物医药有限公司 一种十八烷二酸单叔丁酯-pfp的制备方法
WO2023069994A1 (en) * 2021-10-20 2023-04-27 Bristol-Myers Squibb Company Immunomodulators
CN118176214A (zh) 2021-10-29 2024-06-11 百时美施贵宝公司 血液癌症的lag-3拮抗剂疗法
WO2023122945A1 (zh) * 2021-12-28 2023-07-06 知和(山东)大药厂有限公司 环状多肽化合物及其用途
KR20240135661A (ko) 2022-01-26 2024-09-11 브리스톨-마이어스 스큅 컴퍼니 간세포성 암종에 대한 조합 요법
KR20240156423A (ko) 2022-03-17 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 경구 생체이용률을 향상시키기 위한 살카프로제이트 염 및 니코틴아미드를 포함하는 약학적 조성물
EP4487226A1 (en) 2022-04-08 2025-01-08 Bristol-Myers Squibb Company Machine learning identification, classification, and quantification of tertiary lymphoid structures
EP4554957A1 (en) * 2022-07-15 2025-05-21 Universiteit Utrecht Holding B.V. Antiviral cyclic compounds
CN119731207A (zh) 2022-08-23 2025-03-28 小野药品工业株式会社 双特异性抗体
WO2024059472A1 (en) * 2022-09-12 2024-03-21 Bristol-Myers Squibb Company Macrocyclic immunomodulators
CN120731228A (zh) 2022-12-21 2025-09-30 百时美施贵宝公司 肺癌的组合疗法
CN120936346A (zh) 2023-03-17 2025-11-11 百时美施贵宝公司 用于改善口服生物利用度的药物组合物
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151634A1 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
MXPA05006828A (es) 2002-12-23 2005-09-08 Wyeth Corp Anticuerpos contra pd-1, y sus usos.
WO2005000878A2 (en) * 2003-06-26 2005-01-06 Migenix Inc. Compositions of lipopeptide antibiotic derivatives and methods of use thereof
JP4361545B2 (ja) 2005-05-09 2009-11-11 小野薬品工業株式会社 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
HRP20151102T1 (xx) 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
EP2141175B1 (en) * 2007-03-26 2016-07-27 The University of Tokyo Process for synthesizing cyclic peptide compound
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
JP2012510429A (ja) 2008-08-25 2012-05-10 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよびその使用方法
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
WO2012074130A1 (ja) 2010-12-03 2012-06-07 国立大学法人東京大学 ペプチドライブラリーの製造方法、ペプチドライブラリー、及びスクリーニング方法
EP2717895A1 (en) 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013010573A1 (en) 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
US9422339B2 (en) 2012-03-29 2016-08-23 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds
HK1207829A1 (zh) * 2012-06-06 2016-02-12 Bionor Immuno As 疫苗
SG11201407837WA (en) 2012-06-06 2014-12-30 Polyphor Ag Beta-hairpin peptidomimetics
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法
KR102389677B1 (ko) 2013-03-15 2022-04-21 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
CN103333227B (zh) * 2013-06-07 2015-10-07 东南大学 转移肿瘤缺失蛋白小分子环肽抑制剂及其制备方法与应用
PT3041468T (pt) 2013-09-06 2018-09-28 Aurigene Discovery Tech Ltd Compostos peptidomiméticos cíclicos como imunomoduladores
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
US10538555B2 (en) 2014-09-11 2020-01-21 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US10406251B2 (en) 2014-11-25 2019-09-10 Bristol-Myers Squibb Company PD-L1 binding polypeptides for imaging
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
LT3458111T (lt) 2016-05-19 2021-05-25 Bristol-Myers Squibb Company Pet vizualizacijos imunomoduliatoriai
EP3535280B1 (en) 2016-11-07 2022-03-16 Bristol-Myers Squibb Company Immunomodulators
US11066445B2 (en) 2017-06-23 2021-07-20 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of PD-1
CN111051332B (zh) 2017-10-03 2024-09-06 百时美施贵宝公司 免疫调节剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151634A1 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions

Also Published As

Publication number Publication date
US10633419B2 (en) 2020-04-28
EA201791046A1 (ru) 2017-09-29
ZA201703295B (en) 2019-06-26
IL252235A0 (en) 2017-07-31
US11358988B2 (en) 2022-06-14
PT3218392T (pt) 2020-09-21
IL252235B (en) 2021-12-01
TW201632541A (zh) 2016-09-16
TN2017000183A1 (en) 2018-10-19
HRP20201692T1 (hr) 2020-12-25
US20230101323A1 (en) 2023-03-30
RS60940B1 (sr) 2020-11-30
SI3218392T1 (sl) 2020-11-30
JP6804442B2 (ja) 2020-12-23
SG11201703754SA (en) 2017-06-29
EA036279B1 (ru) 2020-10-21
US20180086793A1 (en) 2018-03-29
AU2020217406A1 (en) 2020-09-03
NZ732676A (en) 2024-03-22
EP3218392B1 (en) 2020-07-29
US11952434B2 (en) 2024-04-09
UY36400A (es) 2016-06-01
DK3218392T3 (da) 2020-10-19
LT3218392T (lt) 2020-10-26
HUE051659T2 (hu) 2021-03-29
PE20171332A1 (es) 2017-09-13
CL2017001171A1 (es) 2017-09-15
CN114652813A (zh) 2022-06-24
BR112017009600A2 (pt) 2017-12-26
KR20170077248A (ko) 2017-07-05
JP2017538682A (ja) 2017-12-28
ES2819285T3 (es) 2021-04-15
TWI700301B (zh) 2020-08-01
SMT202000578T1 (it) 2020-11-10
US20160137696A1 (en) 2016-05-19
KR102569176B1 (ko) 2023-08-22
CA2967344A1 (en) 2016-05-19
EP3778622A1 (en) 2021-02-17
CO2017004736A2 (es) 2017-09-20
MA39285A (fr) 2016-05-19
WO2016077518A1 (en) 2016-05-19
CN107108698A (zh) 2017-08-29
MX2017006283A (es) 2017-12-04
AU2015346343A1 (en) 2017-06-29
MY184870A (en) 2021-04-28
US20200216498A1 (en) 2020-07-09
EA201791046A8 (ru) 2018-01-31
CY1123598T1 (el) 2022-03-24
CA2967344C (en) 2023-09-19
US9856292B2 (en) 2018-01-02
MX384024B (es) 2025-03-14
PL3218392T3 (pl) 2021-01-11
EP3218392A1 (en) 2017-09-20
PH12017500858A1 (en) 2017-11-06
CN107108698B (zh) 2022-04-29

Similar Documents

Publication Publication Date Title
US11952434B2 (en) Immunomodulators
EP3535280B1 (en) Immunomodulators
EP3233887B1 (en) Immunomodulators
EP3271373B1 (en) Immunomodulators
IL261408A (en) Immunomodulators
WO2019070643A1 (en) IMMUNOMODULATORS
EP3253775A1 (en) Immunomodulators
EP3233888A1 (en) Immunomodulators
HK40044642A (en) Macrocyclic peptides useful as immunomodulators
BR112017009600B1 (pt) Peptídeos macrocíclicos úteis como imunomoduladores
HK1238650A1 (en) Macrocyclic peptides useful as immunomodulators
HK1238650B (en) Macrocyclic peptides useful as immunomodulators

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ GILLMAN, KEVIN W.; GOODRICH, JASON; BOY, KENNETH M.; ZHANG, YUNHUI; MAPELLI, CLAUDIO; POSS, MICHAEL A.; SUN, LI-QIANG; ZHAO, QIAN; MULL, ERIC; GILLIS, ERIC P.; SCOLA, PAUL MICHAEL; LANGLEY, DAVID R. AND MEANWELL, NICHOLAS A.

FGA Letters patent sealed or granted (standard patent)